Bronchial Asthma
Conditions
Interventions
Fixed airflow obstruction asthma group:Nil
Reversible airflow obstruction asthma group:
Healthy control group:Nil
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria of asthma group with fixed airflow obstruction: 1. Age 40-80, male or female; 2. Deny smoking history or smoking cessation for more than 3 years and previous smoking index<15 packs/year, and deny occupational dust and smoke exposure history; 3. It conforms to the diagnostic criteria for asthma in GINA 2020 and China's Guidelines for the Prevention and Treatment of Bronchial Asthma. The duration of the disease is = 5 years, and it has been diagnosed and treated regularly for more than 1 year. At present, the severity is moderate or severe, and the staging is chronic; 4. The recent pulmonary function report indicates that the pulmonary ventilation dysfunction is mainly obstructive, and FEV1/FVC is less than 0.7 after the administration of bronchodilator; 5. The subject signed a written informed consent to participate in the study. Inclusion criteria of reversible airflow obstruction asthma group: 1. Age 40-80, male or female; 2. Deny smoking history or smoking cessation for more than 3 years and previous smoking index<15 packs/year, and deny occupational dust and smoke exposure history; 3. It conforms to the diagnostic criteria for asthma in GINA 2020 and China's Guidelines for the Prevention and Treatment of Bronchial Asthma. The duration of the disease is = 5 years, and it has been diagnosed and treated regularly for more than 1 year. At present, the severity is moderate or severe, and the staging is chronic,; 4. The recent pulmonary function report indicates that the pulmonary ventilation dysfunction is mainly obstructive, and FEV1/FVC = 0.7 after the administration of bronchodilator; 5. The subject signed a written informed consent to participate in the study. Inclusion criteria of healthy control group: 1. Age 40-80, male or female; 2. Deny smoking history or smoking cessation for more than 3 years and previous smoking index<15 packs/year, and deny occupational dust and smoke exposure history; 3. Normal pulmonary function, no history of basic lung diseases; 4. The subject signed a written informed consent to participate in the trial.
Exclusion criteria
Exclusion criteria: Exclusion criteria for fixed airflow obstruction asthma group and reversible airflow obstruction asthma group: 1. Complicated with pneumonia, pulmonary interstitial fibrosis, active pulmonary tuberculosis, obstructive sleep apnea hypopnea syndrome and other respiratory system related diseases, with a previous history of pulmonary surgery; 2. Accompanied by the following diseases or conditions: serious, progressive or uncontrolled diseases of cardiovascular, liver, kidney, hematopoietic system and nervous system; Malignant tumor; Or immunosuppression (including immunosuppression or HIV infection); 3. Accompanied with severe gastrointestinal diseases (such as inflammatory bowel disease [IBD] or irritable bowel syndrome [IBS]), severe diarrhea (more than 3 watery stools lasting for more than 3 days) and constipation (less than 2 stools per week with difficulty in defecation) in the last 3 weeks; 4. Systemic application of antibiotics, systemic glucocorticoids (including oral, intravenous [IV] or intramuscular [IM]), microecological agents or traditional Chinese medicine in the last 4 weeks; 5. Overweight (BMI>28.0kg/m2), pregnant and lactating women; 6. Poor compliance, unable to cooperate with clinical observation and specimen collection. Exclusion criteria for healthy control group: 1. Suffering from hypertension, diabetes, coronary heart disease, liver and kidney failure, nervous system disease, mental disease, malignant tumor, etc; Or immunosuppression (including immunosuppression or HIV infection); 2. Accompanied with severe gastrointestinal diseases (such as inflammatory bowel disease [IBD] or irritable bowel syndrome [IBS]), severe diarrhea (more than 3 watery stools lasting for more than 3 days) and constipation (less than 2 stools per week with difficulty in defecation) in the last 3 weeks; 3. Systemic application of antibiotics, systemic glucocorticoids (including oral, intravenous [IV] or intramuscular [IM]), microecological agents or traditional Chinese medicine in the last 4 weeks; 4. Overweight (BMI>28.0kg/m2), pregnant and lactating women; 5. Poor compliance, unable to cooperate with clinical observation and specimen collection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Microbial species via 16s rRNA;sputum cell count;Scale of Classification and Determination of Constitution in Traditional Chinese Medicine;Pulmonary Function;YKL-40; | — |
Secondary
| Measure | Time frame |
|---|---|
| routine analysis of blood;BMI; clinical characteristics;Serum total IgE;FeNO; | — |
Countries
China
Contacts
Public ContactYinji Xu
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed